Efamat 600mg Tablet (Efavirenz 600)

Efamat 600mg Tablet is an antiviral medicine with Efavirenz as an active ingredient. It is prescribed to treat HIV (human immunodeficiency virus) infection and manage AIDS. It works by preventing viruses from multiplying and boosting immunity to fight against the infection. Thereby reducing the amount of virus in the body. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

HIV

The human body reacts differently to Efamat 600mg Tablet(Efavirenz 60mg). Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention.

Some of the common side effects of Efamat 600mg:
● Fatigue
● Pain
● Decreased appetite
● Headache
● Nausea
● Dizziness
● Vomiting
● Increased liver enzymes
● Insomnia (difficulty sleeping)
● Sleepiness
● Abnormal dreams
● Anxiety
● Itching
● Difficulty in paying attention
● Rash
● Abdominal pain
● Diarrhea
● Depression
However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Take Efamat 600mg Tablet(Efavirenz 60mg) in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken on an empty stomach. Never skip a dose or double dose.

● Carey, D. (2014). Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study. Journal of the International AIDS Society, 17.
● Maggiolo, F. (2009). Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy, 64(5), 910-928.
● Vrouenraets, S. M., Wit, F. W., Tongeren, J. V., & Lange, J. M. (2007). Efavirenz: a review. Expert opinion on pharmacotherapy, 8(6), 851-871.
● Manosuthi, W., Kiertiburanakul, S., Sungkanuparph, S., Ruxrungtham, K., Vibhagool, A., Rattanasiri, S., & Thakkinstian, A. (2006). Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. Aids, 20(1), 131-132.
● ENCORE1 Study Group. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
● ENCORE1 Study Group. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802.